▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #3044 by analyst upside · 2026-11-13
LGND
Ligand Pharmaceuticals Incorporated
Healthcare · Market Cap $6B · P/E 127.0x
ANALYST PRICE TARGET
+14.2%
implied upside to consensus target
Current Price $316.27
Consensus Target $361.27
Bull Target $406.0
Bear Target $335.0
Analysts Covering 11
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
8
Hold
0
Sell
0
52-Week Low $175.89
52-Week High $326.63
YTD Return +66.4%
FUNDAMENTALS
Market Cap $6B
P/E Ratio (TTM) 127.0x
Forward P/E 26.5x
EPS (TTM) $2.49
PEG Ratio 1.53
Dividend Yield N/A
Revenue (TTM) $254M
Profit Margin 20.3%
52-WEEK RANGE
52-Week Low $175.89
52-Week High $326.63
Current Price $316.27
Bear Target $335.0
Bull Target $406.0
● Now $316.27 ● Target $361.27
TRADING DATA
Avg Volume 226K
YTD Return +66.4%
Analyst Count 11
Consensus Buy
Upside to Target +14.2%
Last Updated 2026-11-13

ANALYST SUMMARY

Ligand Pharmaceuticals Incorporated (LGND) is currently trading at $316.27 with a Wall Street consensus price target of $361.27, implying potential upside of 14.2% over the next 12 months. 11 analysts currently cover LGND, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $406.0, while the most cautious has a target of $335.0.

LGND operates in the Healthcare sector with a market capitalisation of $6B. The stock is up 66.4% year-to-date and is currently trading near the upper end of its 52-week range of $175.89 – $326.63.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

TGTX +20.0%
TG Therapeutics, Inc.
$10B · P/E 96.4x · Buy
SOLV +10.8%
Solventum Corporation
$15B · P/E 99.8x · Hold
TFX +9.8%
Teleflex Incorporated
$6B · P/E 75.4x · Buy
HAE +17.8%
Haemonetics Corporation
$6B · P/E 54.3x · Buy
AMRX +11.9%
Amneal Pharmaceuticals, Inc.
$8B · P/E 54.2x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for LGND, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citigroup - Reiterated
Buy → Buy 2026-11-05 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-10-30 Building track record
Barclays ● Initiated
Overweight 2026-09-25 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-24 31% win rate (48 calls)
Citigroup - Reiterated
Buy → Buy 2026-09-23 Building track record
Leerink Partners ● Initiated
Outperform 2026-08-14 29% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-07 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-06 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
72
out of 100
Coverage depth
19/30
Consensus clarity
26/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →